Key Points Interested in Amgen Inc.? Here are five stocks we like better. Amgen said its strong first-quarter results support ...

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not ...

Drug companies are racing to catch up to Eli Lilly and Novo Nordisk, seeking to require fewer shots or reduce side effects.

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN.

With the help of GLP-1 treatments, patients living with obesity and obesity-related conditions can define success on their ...

Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 9:20 AM EDTCompany ParticipantsPeter Griffith - Executive ...

In the persistence and adherence analysis, which looked at 28 studies including 267,542 patients, Amgen found that 69% of ...

April 27 (Reuters) - The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) has proposed withdrawing approval of Amgen's drug for rare autoimmune diseases, citing a ...

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.